Background {#Sec1}
==========

Copy number variants (CNVs; chromosomal deletions and duplications) have been identified as significant aetiological factors in a range of neurodevelopmental disorders including intellectual disability (ID) \[[@CR1]\], autism \[[@CR2]\], epilepsy \[[@CR3]\] and psychiatric disease \[[@CR4]\]. The detection of a causative CNV in a patient is valuable for genetic counselling and, in some cases, guiding clinical management. The observation of a rare chromosomal abnormality in a patient with a rare neurological phenotype has occasionally been the vital clue leading to the identification of genes and pathways critical to brain development \[[@CR5], [@CR6]\]. A limited number of previous genome-wide CNV studies have focused on patients with both epilepsy and ID \[[@CR7]--[@CR10]\]. We set out to investigate the rare CNVs present in a series of 80 patients with ID/developmental delay (DD) and childhood-onset epilepsy. Our aims were: to determine the frequency of pathogenic CNVs in the cohort; to define the clinical features of patients carrying pathogenic CNVs; to identify any sub-groups of patients particularly enriched for pathogenic CNVs; and to highlight candidate genes for epilepsy and ID/DD.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

Participants were recruited between 2010 and 2014. Participants were 80 unrelated patients (49 adults and 31 children) identified through medical genetics, learning disability and paediatric neurology clinics around Wales (see Additional file [1](#MOESM1){ref-type="media"}: Table S1 for further demographic information). Participants lacked a molecular diagnosis and had not previously undergone high resolution genome-wide cytogenetic analysis (\<1 Mb resolution). The majority of participants had previously been tested by karyotype (61/80) combined with additional cytogenetic and molecular tests (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Patients with known significant congenital brain malformations were excluded (e.g. malformations of cortical development, porencephaly, holoprosencephaly or intracerebral vascular malformations). CNV rates in the general population were estimated from 929 control subjects derived from the Wellcome Trust Case Control Consortium 2 National Blood Donors Cohort \[[@CR11]\]. These were blood donors recruited by UK Blood Services and are therefore similar in ethnic origin to our mostly white British cohort. Controls were genotyped on Illumina OmniExpress single nucleotide polymorphism (SNP)-arrays.

Ethics approval and consent to participate {#Sec4}
------------------------------------------

The study was approved by the Research Ethics Committee for Wales (09/MRE09/51). Informed consent for testing and publication was obtained from all participants (or their parents/legal guardians).

Microarray analysis {#Sec5}
-------------------

Genomic DNA was extracted from blood (*n =* 73) or saliva (*n =* 7). Samples were tested on one of three platforms: (i) Illumina610-Quad SNP-array (*n =* 20); (ii) Illumina OmniExpress SNP-array (*n =* 36); or (iii) microarray-based comparative genomic hybridization (array CGH) using a BlueGnome CytoChip ISCA 8x60k v2.0 array (*n =* 24). Validation testing was performed by fluorescent *in situ* hybridisation, multiplex ligation-dependent probe amplification (MLPA) or by testing on a second array platform. The method for identifying CNVs depended on the array platform. SNP-array data was called using PennCNV \[[@CR12]\]. Called CNVs were filtered by probe number (10 or more) and gene content (at least one). We excluded CNVs which had 50 % or greater overlap with a CNV in the control cohort. However, for key genomic regions known to harbour recurrent CNVs associated with neurodevelopmental disorders which demonstrate incomplete penetrance (1q21.1, 15q11.2, 15q13.3, 16p11.2 and 16p13.11) we allowed CNVs to be present at low frequency in controls (\<1 %). Analysis focused on deletions and duplications larger than 100 kb and 250 kb respectively (50 kb for disease regions). Array CGH data was referenced against same sex control DNA (Promega) and analysed using Illumina BlueFuse Multi (v3.1) software, with data filtered on consecutive probes (3 or more) and size (as above). Imbalances detected by array CGH were interpreted by comparison with data from the Database of Genomic Variants, International Standards for Cytogenomic Arrays consortium and local laboratory data. Coordinates are based on hg19/GRCh37. Statistical comparisons were made using Fisher's exact test calculated with an online tool \[[@CR13]\]. Parents and additional family members were analysed, where available, to determine if a CNV had arisen *de novo* or segregated with disease in a family. We assessed the clinical significance of CNVs based on their size, type, inheritance and whether they contained known disease genes. We were guided by the approach set out in previous publications \[[@CR7], [@CR14]\]. Based on this assessment some CNVs were annotated as 'pathogenic' (e.g. a *de novo* deletion of a proven disease gene/region) or 'likely pathogenic' (e.g. large CNVs containing genes/regions previously linked to disease). Other CNVs were considered to be of unknown significance.

*SCN1A* gene testing {#Sec6}
--------------------

A subgroup of patients was tested for intragenic *SCN1A* mutations. Sequencing of the complete coding region and flanking sequence of the gene was performed by bidirectional Sanger sequencing (*n =* 4) or by targeted next-generation sequencing (NGS) (*n =* 11). Sequencing (Sanger or NGS) covered all the coding sequence of *SCN1A* along with 20 bp of flanking intron or untranslated region (UTRs). Sequencing did not cover the promoter, deep intronic regions or the rest of the UTRs. *In silico* analysis of detected variants included PhyloP \[[@CR15]\], SIFT \[[@CR16]\], Grantham distance \[[@CR17]\], PolyPhen-2 \[[@CR18]\] and CADD \[[@CR19]\]. We also searched the Exome Aggregation Consortium (ExAC) database \[[@CR20]\], dbSNP \[[@CR21]\], ClinVar \[[@CR22]\] and an *SCN1A* mutation-specific database \[[@CR23]\]. Nucleotide and protein positions are based on NCBI Reference Sequences NM_001165963.1 and NP_001159435.1 respectively \[[@CR24]\].

Results and discussion {#Sec7}
======================

The 80 patients had a range of epilepsy phenotypes including epileptic encephalopathy (EE, *n =* 25), non-lesional focal epilepsies (*n =* 22), and genetic generalised epilepsy with ID (GGE-ID, *n =* 22) (Table [1](#Tab1){ref-type="table"}). In the remainder, the epilepsy phenotype was unclassified or unknown. We found 22.5 % (18/80) of the cohort carried at least one rare CNV (Table [2](#Tab2){ref-type="table"}). Three patients had more than one rare CNV. The average size of the CNVs was 647 kb (median 488 kb). We identified 8 CNVs considered to be likely (*n =* 3) or clearly pathogenic (*n =* 5) (Table [2](#Tab2){ref-type="table"}). One patient (R660) had one clearly and one likely pathogenic CNV. This meant 7 (8.8 %) of our patients had pathogenic or likely pathogenic CNVs. Additional rare variants of uncertain clinical significance (VUS) were present in 11 further patients. We compared the frequency of CNVs in patients and controls. We found that large (\>500 kb) low frequency (\<1 %) genic CNVs were marginally more common in patients (13 %, 10/80) compared with controls (11 %, 105/929). However, this difference was not statistically significant (*P* = 0.71). The majority of patients had previously been tested by karyotype which will have depleted larger CNVs from the cohort.Table 1Epilepsy syndromes in the cohort at recruitmentSyndromeNumberEpileptic encephalopathy (EE) Lennox-Gastaut syndrome9 Dravet syndrome3 West syndrome2 Myoclonic astatic epilepsy2 Epilepsy of infancy with migrating focal seizures2 Ohtahara syndrome1 Epilepsy with continuous spikes and waves during sleep1 Unclassified EE with onset in infancy5Genetic generalised epilepsy with intellectual disability (GGE-ID) Myoclonic epilepsy3 Progressive myoclonic epilepsy1 Other GGE-IDs18Non-lesional focal epilepsies22Unclassified epilepsy2Unknown9Total80Table 2Rare CNVs detected in 80 patients with ID/DD and epilepsySubjectAgeSexClinical featuresSeizure onsetSyndromeSeizure typesCytobandCNV TypeCoordinatesSize (Kb)TestsStatusInterpretationGenesR12510 mFSevere DD, cleft palate3 mEIMFSFE, EBCS, CSE2q24.3Del163823021--1679587234,136c/fDNPath*SCN3A, SCN2A, SCN1A, SCN9A, SCN7A* & 8 othersR35115yMModerate DD, poor coordination, joint contractures, mildly dysmorphic3 mDravet[FS]{.ul}, GTCS, CSE, M2q24.3Del166842637--16691893276c/dDNPath*SCN1A*R4047yFMild DD, ASD8 mWest[IS]{.ul}, Abs16p11.2Del29595483--30198151603b/e,fDNPath*DOC2A, KIF22, MAPK3, PRRT2, QPRT, SEZ6L2* & 24 othersR66021yMMod-severe ID, challenging behaviour, ASD, depression, dysmorphic8 mGGE-IDAbs, M, FDS, EBCS9q34.3Del140707889--140890373182b/eDNPath*CACNA1B, EHMT1*3p14.2Dup59736299--610233551,287b/ePatLikely*FHIT*3p22.1Del41359533--41824555465b/eMatVUS*ULK4*R91122yFMod ID, small head, mildly dysmorphic10yFEFDS, GTCS2q22.3Del148691873--148818437127b/eDNPath*MBD5, ORC4*R91320yMMod-severe ID, challenging behaviour, ASD10 mFE[FS]{.ul}, FDS, EBCS16p13.11Dup15512574--16262571750b/eMatLikely*ABCC1, C16orf45, FOPNL, KIAA0430, MIR484, MYH11, NDE1*R34527yFMild ID, dysmorphic\<6yGGE-IDM, Abs, GTCS2q13Del111392259--1130947931,703b/ePatLikely*BUB1, BCL2L11, ANAPC1, MERTK, FBLN7* & 5 othersR5826yFSevere ID, scoliosis\<8yGGE-IDAt, Abs, M1q21.1Dup145625979--14572364598a/eMatVUS*CD160, RNF115*R74^a^51yFMild-mod ID, depression3 mFE[FS]{.ul}, FE, EBCS1p21.1Del104167778--104297867130a/eUVUS*AMY1A, AMY1B, AMY1C, AMY2A*R10132yMID, seizures\<16yUU11q22.3Del109173027--109325299152b/ePatVUS*C11orf87*R19819yMSevere ID, ASD, mild right hemiparesis7 mLGS[FE]{.ul}, IS, Abs, NCS, GTCS, At, FDSXq28Del150589930--150811921222c/ndUVUS*PASD1*R52823yMSevere ID, challenging behaviour, ASD, dysmorphic, regression11yFEFE, Abs15q13.3Dup32019919--32514341494b/eUVUS*CHRNA7*R60541yMID, seizures\<16yUU15q11.2Dup22383292--23272733889b/ePatVUS*CYFIP1, NIPA1, NIPA2, TUBGCP5* & 8 others8p23.1Del11713852--12204679491b/eMatVUS*CTSB, FAM66D, FAM86B1, USP17L2, ZNF705D* & 6 othersR622^a^28yFModerate ID, challenging behaviour6 mGGE-ID[IS]{.ul}, GTCS, M18p11.22Dup10042023--10581304539b/eMatVUS*APCDD1, NAPG*R65021yMMild ID, thin habitus, depression18 mGGE-IDAbs, M, GTCS15q13.3Dup32029693--32514926485a/ndUVUS*CHRNA7*15q14Del34700297--34807869108a/ndUVUS*GOLGA8A*R7869yMModerate DD, Leg hypertonia, dystonia2yGGE-ID (M)M, Abs, At21q21.3Del27715263--27955385240a/eMatVUS*CYYR1*R93115yFSevere DD, ASD, dysmorphic, microcephaly12yGGE-ID[GTCS]{.ul}7q11.22Del71815170--72305671491b/ePatVUS*CALN1, MIR4650-1, MIR4650-2, SBDSP1, TYW1B*R9815yFSevere DD, regression, ASD, leg hypertonia1wGGE-IDAbs, At, M, T3p26.3Dup726675-1301830575c/ndUVUS*CNTN6*Age (at recruitment) and seizure onset in y(ears), m(onths) or w(eeks). Clinical features: *ID* intellectual disability, DD, developmental delay, *ASD* autism spectrum disorderSyndrome, electroclinical syndrome or main epilepsy type at recruitment: Dravet, Dravet syndrome; EIMFS, epilepsy of infancy with migrating focal seizures: *FE* focal epilepsy, *GGE-ID*, genetic generalised epilepsy with ID, *LGS* Lennox-Gastaut syndrome, *U* unknown, *West* West syndromeSeizure types: *Abs* absence, *At* atonic, *CSE* convulsive status epilepticus, *EBCS* evolution to bilateral or convulsive seizures, *FDS* focal dyscognitive seizures, *FS* febrile seizures, *GTCS* generalised tonic-clonic seizures, *IS* infantile spasms, *M* myoclonic, *NCS* non-convulsive status epilepticus, *T* tonic, seizure type at presentation is underlined (when known)CNV type, Dup(lication) or Del(eletion). Coordinates, chromosome position of first/last abnormal probes based on hg19/GRCh37. Tests, primary array/confirmation method: (a) Illumina610-Quad SNP-array, (b) Illumina OmniExpress SNP-array, (c) BlueGnome CytoChip array CGH, (d) quantitative PCR, (e) Illumina Exome BeadChip or custom Illumina SNP array, (f) fluorescence *in situ* hybridization, and (nd) not done. Status: DN, *de novo*; inherited Pat(ernally); Mat(ernally) or U(nknown). Interpretation (of clinical significance): Path(ogenic); Likely, likely pathogenic; VUS, variant of uncertain significance^a^Patients R622 and R74 had pathogenic *SCN1A* mutations which suggests these two CNVs are likely to be benign

Pathogenic CNVs {#Sec8}
---------------

The five clearly pathogenic CNVs were all *de novo* deletions. We found a *de novo* 127 kb deletion of 2q23.1 in a woman with moderate ID, mildly dysmorphic facial features (long face, thin upper lip, slightly upslanting palpebral fissures, long nose) and seizures. The deletion disrupted the first two non-coding exons of the *MBD5* gene. *MBD5* encodes a member of the methyl-CpG-binding domain family. The MBD5 protein binds to methylated DNA and is thought to regulate gene expression by controlling chromatin modification \[[@CR25]\]. Deletions of the 5′- UTR of *MBD5* result in reduced expression of the gene \[[@CR26]\]. Common clinical features in *MBD5* patients include ID/DD, seizures, language impairment, microcephaly, mild craniofacial dysmorphism and autism spectrum disorders (ASD) \[[@CR26]--[@CR28]\]. Interestingly, patients with CNVs confined to the 5′-UTR (like R911) have phenotypes similar to patients with larger 2q23.1 deletions. This highlights the critical impact of non-coding sequence at the locus \[[@CR29]\].

We observed a *de novo* 182 kb deletion at 9q34.3 involving *EHMT1* in an adult male (R660) with moderate-to-severe ID, dysmorphic features (hypertelorism, mid face hypoplasia, prognathism), aggressive behaviour, autistic features, depression and epilepsy. Deletions at 9q34 involving *EHMT1* are responsible for Kleefstra syndrome \[[@CR30]\]. *EHMT1* encodes a histone methyltransferase involved in transcriptional repression. EHMT1 is known to interact with MBD5 and they work together to regulate gene expression \[[@CR25]\]. Characteristic features of Kleefstra syndrome include ID/DD, microcephaly, psychiatric disorders, severe behavioural problems, dysmorphic features, hypotonia, heart defects and seizures \[[@CR31]\]. In addition to truncating *EHMT1* the 9q34 deletion involved the adjacent *CACNA1B* gene. *CACNA1B* encodes a subunit of a voltage-dependent calcium channel expressed on neurons. Mutations in other N-type voltage-dependent calcium channel subunits have been linked to a wide range of paroxysmal disorders including periodic paralysis \[[@CR32]\], familial hemiplegic migraine \[[@CR33]\], myoclonus-dystonia syndrome \[[@CR34]\], childhood absence epilepsy \[[@CR35]\] and idiopathic generalized epilepsy \[[@CR36]\]. Therefore, it is possible that haploinsufficiency of *CACNA1B* may have contributed to the patient's epilepsy phenotype. Patient R660 also had a paternally-inherited 1.3 Mb duplication involving the *FHIT* gene (considered to be likely pathogenic). The *FHIT* gene is a member of the histidine triad gene family. *FHIT* encodes diadenosine 5′,5‴-P1,P3-triphosphate hydrolase, an enzyme involved in purine metabolism. Rare CNVs involving *FHIT* have previously been described in autism \[[@CR37], [@CR38]\]. R660 carried a third rare CNV, a maternally-inherited 465 kb deletion at 3p22.1 involving *ULK4. ULK4* encodes a serine/threonine kinase. Expression of the *ULK4* gene is neuron-specific and developmentally regulated \[[@CR39]\]. This third CNV was considered to be a VUS, although deletions in *ULK4* have recently been reported as a potential risk factor for schizophrenia \[[@CR39]\].

The third clearly pathogenic CNV was a *de novo* 603 kb 16p11.2 deletion in a girl with mild DD, ASD and infantile spasms (seizure free following treatment). Seizures are a common feature of 16p11.2 deletion syndrome along with ASD, ID/DD, psychiatric disease and increased risk of obesity \[[@CR40], [@CR41]\]. The reciprocal duplications at 16p11.2 locus have also been associated with epilepsy including infantile spasms \[[@CR7], [@CR42]\]. The last two clearly pathogenic CNVs were both *de novo* deletions at 2q24.3: one was 76 kb in size and deleted exons 4 to 28 of the *SCN1A* gene; the other was 4.1 Mb and deleted 13 genes including *SCN1A. SCN1A* encodes a voltage-gated sodium channel which is essential for the generation and propagation of action potentials in neurons. Mutations in *SCN1A* cause a spectrum of seizure disorders including familial febrile seizures, generalised epilepsy with febrile seizures plus and Dravet syndrome (severe myoclonic seizures of infancy) \[[@CR43]--[@CR45]\]. Typical features of these disorders are seizure onset in infancy with fever sensitivity. Severe manifestations of *SCN1A*-related disease include pharmacoresistant seizures, ID/DD, ataxia and autistic behaviour \[[@CR46], [@CR47]\]. Patient R125, who had the larger of the two deletions, had a severe phenotype with poor seizure control, severe DD and a cleft palate. These additional features may be due to haploinsufficiency of other genes in the region. The deletion in R125 included *SCN2A*, *SCN3A* and *SCN9A*. All three of these genes encode voltage-gated sodium channels which have been linked to epilepsy \[[@CR48]--[@CR50]\]. The patient's epilepsy phenotype was considered to be epilepsy of infancy with migrating focal seizures (EIMFS). A number of patients with 2q24.3 deletions and EIMFS -like phenotypes have recently been reported \[[@CR51], [@CR52]\]. Patient R351, who had the smaller of the 2q24.3 deletions, had previously undergone *SCN1A* sequencing which had not detected their multi-exon deletion. This highlights that DNA sequencing alone is insensitive to CNVs and that dose-sensitive techniques (e.g. array CGH or MLPA) are required to detect a significant proportion of *SCN1A* mutations \[[@CR53]\].

Two further likely pathogenic CNVs were found. One was a paternally-inherited 1.7 Mb deletion of 2q13 in a female patient (R345) with mild ID, small ventricular septal defect, facial dysmorphism (long face, retrognathism, broad nasal root, hypertelorism, mild facial asymmetry) and epilepsy. Deletions at 2q13, similar to the one found in patient R345 have been reported in other patients with DD/ID \[[@CR54], [@CR55]\]. Common manifestations include facial dysmorphism, autistic features, seizures and cardiac malformations. Previously reported 2q13 deletions have been inherited from an apparently normal parent, consistent with incomplete penetrance. Interestingly, the father of R345 shares similar facial features, but has no history of ID or epilepsy. The third likely pathogenic CNV was a maternally-inherited 750 kb duplication of 16p13.11 in a man with mild ID, ASD, seizures and a history of aggressive episodes. We considered the 16p13.11 duplication to be likely contributory as there was a family history of childhood epilepsy in the patient's mother and a maternal uncle (untested). Deletions in the 16p13.11 region are clear risk factors for neurodevelopmental disorders including epilepsy \[[@CR3], [@CR56]\]. There is also evidence that duplications at 16p13.11 predispose to neurodevelopmental disorders (ASD, schizophrenia and ID) \[[@CR57]--[@CR60]\] and have been reported in patients with epilepsy \[[@CR61]\]. Several further CNVs at genomic 'hot spots' were observed (duplications at 1q21.1, 15q11.2 and 15q13.3). These duplications were all inherited from unaffected parents and overlapped CNVs in the control cohort. They were therefore considered to be VUS. It remains possible that some of these VUS have contributed to disease risk. For example, there is evidence that *CHRNA7* duplications may subtly increase the risk of neurodevelopmental disorders including ID \[[@CR62]\]. However, further large-scale epidemiological studies are required to fully define these risks. Among the non-'hotspot' CNVs of uncertain significance we found a 575 kb duplication involving the first 4 exons of *CNTN6*. This duplication was identified in a 5-year-old girl with severe DD, ASD, bilateral lower limb hypertonia and early-onset seizures. *CNTN6* is an interesting candidate gene for neurodevelopmental disorders as it encodes a neural adhesion molecule that operates in the formation, maintenance and plasticity of neuronal networks. In addition, CNVs involving *CNTN6* have been reported in patients with DD/ID and autistic features \[[@CR2], [@CR63]--[@CR65]\].

*SCN1A* mutations {#Sec9}
-----------------

Struck by finding two deletions involving *SCN1A* we realised that this key monogenic cause of epilepsy had not been extensively pre-screened in our cohort (only 9/80). The majority of recruits were adults (*n =* 49) who were initially investigated before *SCN1A* testing was available. Furthermore, in contrast to paediatric settings, the significance of *SCN1A* mutations for adult patients is often neglected \[[@CR66]\], usually because key elements of early history (e.g. age of onset, initial seizure types) are not available. We therefore selected a group of patients with early-onset epilepsy for *SCN1A* sequencing. Of the 38 patients with seizure onset before 12 months, 6 had previously had normal testing for *SCN1A* while 3 others had pathogenic CNVs. Fifteen of the remaining 29 patients were prioritized for testing based on clinical features (e.g. a history of myoclonic or febrile seizures). This found 4 pathogenic *SCN1A* mutations (Table [3](#Tab3){ref-type="table"}). All four patients had seizure onset in early infancy (6 months or before) and ongoing seizures despite anticonvulsant therapy. Three of the mutations were missense mutations. The fourth was a 4 base duplication leading to a frameshift early in the gene. *In silico* analysis indicated the missense mutations were all deleterious changes affecting conserved residues (Table [3](#Tab3){ref-type="table"}). One missense mutation segregated with epilepsy and ID phenotypes in the patient's family (the proband's two affected siblings and their mildly-affected mother) the others were all *de novo*. In combination with the array data these results indicate that at least 6/80 (7 %) of our cohort had *SCN1A*-related seizure disorders.Table 3*SCN1A* mutations in the cohortSubjectR622R74R710R769Age28y51y24y3ySexFFFFClinical featuresModerate ID, challenging behaviourMild-mod ID, depressionModerate ID, ataxia, stroke-like episodesMod-severe DD, poor coordinationSeizure onset6 m3 m6 m5dSyndromeGGE-IDFEPMECSWSSeizure typesIS, GTCS, MFS, FE, EBCSC-CSE, M, FDS, EBCST, GTCS, CSE, FE, At, Abs, MGenomic coordinatesChr2 g.166915177 \_166915180dupChr2 g.166915162 G \> AChr2 g.166913001 G \> CChr2 g.166848780 C \> TcDNAc.283_286dupc.301C \> Tc.393C \> Gc.5005G \> AProteinp.Gly96Glufs\*24p.Arg101Trpp.Ser131Argp.Ala1669ThrInheritance*De novoDe novo*Segregates with phenotype*De novo*PhyloP-0.91 (highly conserved)0.89 (highly conserved)0.86 (highly conserved)Grantham distance-101 (moderate)110 (moderate)58 (small)SIFT-0 (deleterious)0.02 (deleterious)0 (deleterious)PolyPhen-2 (HumVar)-0.982 (probably damaging)0.368 (benign)1 (probably damaging)CADD (PHRED-scaled)-34 (top 0.1 %)22.3 (top 1 %)26.1 (top 1 %)ExAC frequency0000dbSNP-rs121917965\--Age (at recruitment) and seizure onset in y(ears), m(onths) or d(ays). Clinical features: *ID* intellectual disability, *DD* developmental delaySyndrome, electroclinical syndrome or main epilepsy type at recruitment: CSWS, epilepsy with continuous spikes and waves during sleep; *FE* focal epilepsy, *GGE-ID* genetic generalised epilepsy with ID, *PME* progressive myoclonic epilepsySeizure types: *Abs* absence, *At* atonic, *C* clonic, *CSE* convulsive status epilepticus, *EBCS* evolution to bilateral or convulsive seizures, *FDS* focal dyscognitive seizures, *FS* febrile seizures, *GTCS* generalised tonic-clonic seizures, *IS* infantile spasms, *M* myoclonic, *T* tonic, seizure type at presentation is underlined. Coordinates are based on hg19/GRCh37. Nucleotide and protein reference sequences were NM_001165963.1 and NP_001159435.1

Conclusions {#Sec10}
===========

We have reported the range of rare CNVs found in a series of 80 Welsh patients with childhood-onset epilepsy and ID/DD. We identified clearly or likely pathogenic CNVs in 7 (8.8 %) of the patients including 5 rare *de novo* deletions. Our results highlight key genes for brain development including drawing attention to *SCN1A* mutations in adults with early-onset pharmacoresistant epilepsy and ID. Our results contribute additional phenotypic descriptions for these rare genomic disorders and support the use of molecular cytogenetic analysis in the genetic evaluation of patients with ID/DD and epilepsy.

Additional file {#Sec11}
===============

Additional file 1: Table S1.A detailed demographic description of the cohort. **Table S2.** Previous cytogenetic and molecular testing in the cohort. (DOCX 17 kb)
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